ArticleBMC gastroenterology2025
Serum complement C3 as a diagnostic biomarker for metabolic dysfunction -associated steatotic liver disease in middle-aged and elderly adults: a cross-sectional study.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- The inner fire: the shifting paradigm of complement system in aging.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease globally, with significant liver fibrosis (SLF) determining clinical outcomes. Although complement activation is involved in MASLD pathogenesis, the clinical significance of circulating complement proteins (C1q, C3, C4, total activity) in aging populations remains unclear. This cross-sectional study aimed to evaluate the association between serum complement levels and MASLD/SLF in middle-aged and elderly adults.
methodsWe recruited 266 consecutive MASLD patients (age ≥ 45) and 150 age- and sex-matched healthy controls from Huadong Hospital. Multivariate logistic regression identified independent predictors of MASLD and SLF. Nonlinear relationships were assessed using restricted cubic splines. Spearman's correlation and mediation analyses explored clinical associations, while ROC curves evaluated diagnostic performance against established non-invasive indices.
resultsMASLD patients showed significantly higher levels of C1q, C3, C4, and total complement activity than controls (P < 0.05). After multivariate adjustment, C3 was independently associated with MASLD (OR = 1.04 per mg/dL, 95% CI: 1.02-1.06; P < 0.001). A nonlinear, inverted U-shaped relationship was observed between C3 and MASLD risk (P = 0.015), with peak risk at 143 mg/dL (OR = 2.53). C3 demonstrated high diagnostic accuracy for MASLD (AUC = 0.80, 95% CI: 0.75-0.85), comparable to validated models. Although lower C3 and C4 were associated with SLF in univariate analysis, this was not sustained after adjustment. No significant association was found between complement levels and SLF.
conclusionsSerum C3 is a promising diagnostic biomarker for MASLD in middle-aged and elderly adults, showing a distinct nonlinear relationship and strong discriminative ability. However, complement levels were not independently associated with liver fibrosis in this population. These findings suggest a potential role for C3 in MASLD diagnosis, but the cross-sectional design precludes causal inference, and further longitudinal studies are needed to confirm its clinical utility and elucidate underlying mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.